ALPINION Launches X-CUBE 90, A High-Performance Ultrasound Diagnostic System
2.3.2021 16:00:00 EET | Business Wire | Press release
ALPINION MEDICAL SYSTEMS Co., Ltd (ALPINION), a medical ultrasound professional, announced that it will launch X-CUBE 90 in March.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210302005348/en/
ALPINION MEDICAL SYSTEMS launches X-CUBE 90, a high-performance ultrasound diagnostic system. X-CUBE 90 provides high-resolution diagnostic images with X+ Architecture. X-CUBE 90 is the top-tier model of X-CUBE, a brand developed by upgrading the existing E-CUBE product line. X-CUBE 90 increases data transmission capacity, data transmission speed, and data processing speed by 4, 10, and up to 14 times compared to existing products. (Photo: Business Wire)
X-CUBE 90 is the top-tier model of X-CUBE, a brand developed by upgrading the existing E-CUBE product line. Compared to the existing models, X-CUBE 90 provides a more detailed image and comfortable user interface and thus a diagnostic environment of greater efficiency.
X-CUBE 90 applied X+ Architecture, an imaging platform independently developed by ALPINION. X+ Architecture is a premium-grade imaging platform created by combining X+ Crystal signature™, a transducer technology with high sensitivity and wideband, and the company’s cutting-edge beamforming and data processing technology, X+ FIT. With ALPINION’s unique algorithm, large-size data are swiftly reorganized, thus clear and high-resolution images are provided.
In addition, X+ FIT, a hardware technology applied to X-CUBE 90, increases data transmission capacity, data transmission speed, and data processing speed by 4, 10, and up to 14 times compared to existing products.
ALPINION applied the following new technologies to X-CUBE 90:
- X+ MicroView: The vascular imaging mode that displays micro blood flow. It clearly displays low-speed blood flow, which has not been possible with Color Doppler at the fast frame rate.
- X+ pSWE: The Point Shear Wave Elastography shows objective quantified stiffness of tissue and the reliability index of a measured result is displayed, ensuring to reduce unnecessary biopsies for patients.
- X+ Assistant: With an optimal scanning protocol registered according to the guideline formulated from practical use, keystroke time is reduced by at least 50%, thus effectively decreasing examination time.
ALPINION CEO Hyunjong Park states, “We are thrilled about the launch of the new high-performance ultrasound diagnostic system, X-CUBE 90. We will continue introducing new products that meet the expectations of healthcare providers and patients around the world.”
About ALPINION MEDICAL SYSTEMS Co., Ltd.
As a subsidiary of ILJIN Group (015860.KS), a company representing South Korea in the field of parts and materials manufacturing, ALPINION MEDICAL SYSTEMS specializes in the development and supply of medical ultrasounds. By independently developing and manufacturing high-quality transducers, diagnostic, and therapeutic ultrasound systems, it is contributing to the elevation in quality of medical services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005348/en/
Contact information
ALPINION
Selina Seo +82-2-3282-0900
marketing@alpinion.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom